Products Categories
| CAS No.: | 910463-68-2 |
|---|---|
| Name: | Sermaglutide |
| Molecular Structure: | |
|
|
|
| Formula: | C187H291N45O59 |
| Molecular Weight: | 4113.57754 |
| PSA: | 1646.18000 |
| LogP: | 5.44520 |
What can I do for you?
Get Best Price
Semaglutide, with the CAS registry number 910463-68-2, a once-weekly glucagon-like peptide-1 receptor agonist, has shown promise in weight management and cardiovascular outcomes. Semaglutide can reduce the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. Among heart failure with preserved ejection fraction (HFpEF) patients and type 2 diabetes, semaglutide led to larger reductions in heart failure–related symptoms and physical limitations and greater weight loss than placebo at 1 year. Semaglutide produced large improvements in HF-related symptoms, physical limitations, exercise function, inflammation, body weight, and N-terminal pro-brain natriuretic peptide, regardless of baseline health status. The benefits of semaglutide extended to all key KCCQ(Kansas City Cardiomyopathy Questionnaire) domains. In overweight or obese non-diabetic individuals, semaglutide had a remarkable and sustained weight loss effect that was well tolerated and safe.
Composition of semaglutide 1.34 mg/ml solution for injection(Applicant's table)
| Name of ingredients | Quantity per ml | Function | Reference to standards |
| Aclive substance | |||
| Semaglutide | 1.34 mg | Active drug substance | Novo Nordisk A/S |
| Excipients | |||
| Disodium phosphate,dihydrate | 1.42 mg | (b)4 | USP/Ph. Eur. |
| Propylene glycol | 14.0 mg | USP/JP/Ph.Eur. | |
| Phenol | 5.50 mga | USP/JP/Ph.Eur. | |
| Hydrochloric acid | q.sb | pH adjustment | USP/JP/Ph.Eur. |
| Sodium hydroxide | q.sb | pH adjustment | USP/JP/Ph.Eur. |
| Water for injections | (b)4 | (b)4 | USP/JP/Ph.Eur. |
a Not provided
b To reach pH 7.4
